AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
1. Amgen and Kyowa Kirin announce ASCEND study results for rocatinlimab. 2. Approximately 2,600 patients being evaluated for long-term safety and efficacy. 3. Most adverse events were mild, with low discontinuation rates due to AEs. 4. Rocatinlimab may become a significant treatment for moderate to severe AD. 5. Further results will be shared at a congress or in a publication.